Fig. 1 · Structure

Documents & Downloads

Bergenin (Cuscutin)

Cat. No. A10127 CAS 477-90-7

Bergenin (Cuscutin) is an isocoumarin isolated from various medicinal plants. Shows mild anti-HIV activity, antihepatotoxic activity and antiulcer activity.

In Stock

Publications for Bergenin

1 publication citing this product

  1. Barai P, .et al. , Behav Brain Res, 2019, Jan 1;356:18-40 PMID: 30118774

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Bergenin has experimental evidence of PPARγ binding and functional activation. A competitive assay using the human PPARγ ligand-binding domain reported a Ki of 2.58 μM, while PPARγ reporter activity increased in treated RAW264.7 macrophages. These results support PPARγ-related activity under the tested conditions; they do not establish target selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 77.28 μM Antiproliferative activity against human A549 cells incubated for 48 to 72 hrs by MTT assay [PMID: 28395218]
C8166 EC50 40 μg/mL Antiviral activity against HIV1 MN in human C8166 cells assessed as reduction of antigen gp120 production by ELISA [PMID: 8786362]
HepG2 IC50 34.56 μM Antiproliferative activity against human HepG2 cells incubated for 48 to 72 hrs by MTT assay [PMID: 28395218]
MCF7 IC50 > 100 μM Antiproliferative activity against human MCF7 cells incubated for 48 to 72 hrs by MTT assay [PMID: 28395218]
Neutrophil IC50 303.12 μM Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay [PMID: 22437110]
PC-3 IC50 > 100 μM Antiproliferative activity against human PC3 cells incubated for 48 to 72 hrs by MTT assay [PMID: 28395218]
SGC-7901 IC50 23.56 μM Antiproliferative activity against human SGC7901 cells incubated for 48 to 72 hrs by MTT assay [PMID: 28395218]
THP-1 IC50 0.208 μM Inhibition of LPS-induced IL6 production in human THP1 cells after 24 hrs [PMID: 25111439]
THP-1 IC50 12.5 μM Inhibition of LPS-induced TNFalpha production in human THP1 cells after 24 hrs [PMID: 25111439]
THP-1 IC50 130 μM Cytotoxicity against human THP1 cells after 24 hrs by MTT assay [PMID: 25111439]
THP-1 IC50 84 μM Cytotoxicity against human THP1 cells after 48 hrs by MTT assay [PMID: 25111439]

11 records · Scroll to view more

In Vitro Studies

In LPS-stimulated RAW264.7 mouse macrophages, 30 μM bergenin reduced IL-6 and TNF-α mRNA and secreted protein after 24 h. In uric-acid-exposed human HK-2 cells, 50–100 μM bergenin altered ABCG2 and SLC2A9 expression; the ABCG2 response at 50 μM depended on PPARγ in knockdown and antagonist experiments. These are model-specific cellular findings, not direct cytokine or urate-transporter inhibition constants. [1,2]

Competitive binding to the PPARγ ligand-binding domain

Biochemical assay · GST-fused human PPARγ ligand-binding domain in a TR-FRET competitive binding assay [1]

Bergenin competed in a PPARγ ligand-binding assay, with a reported Ki of 2.58 μM. Rosiglitazone was the positive comparator (Ki 0.02 μM). This binding result does not establish receptor selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to the human PPARγ ligand-binding domainKi 2.58 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
3 h
Method
Cell-free competitive ligand-binding assay at room temperature.
Reported limits
Exact tested concentration series, compound vehicle and Ki fitting procedure were not specified in the relevant methods. No dosing recommendation is inferred.
Methods and source locations

Compound reported in the paper: Bergenin

Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.

Chemicals and Reagents; Competition Binding Assay; PPARγ activation Results and Figure 7B

Binding to the human PPARγ ligand-binding domain: LanthaScreen TR-FRET competitive binding assay; 520/495 nm emission ratio — Competition Binding Assay; Activation of Bergenin on PPARγ; Figure 7B

Macrophage cytokine suppression and PPARγ reporter activity

Cell-based study · RAW264.7 mouse macrophages; cytokine, viability and PPARγ reporter endpoints [1]

At 30 μM, bergenin reduced LPS-stimulated IL-6 and TNF-α mRNA and secreted protein in RAW264.7 cells. PPARγ reporter activity increased in RAW264.7 cells at 10 and 30 μM. Bergenin alone did not reduce MTT viability over 1–30 μM under the tested conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-6 and TNF-α mRNA and secreted proteinDirection and significance Reduced at 30 μM; p < 0.05 or p < 0.01 versus LPS group, depending on endpoint[1]
Macrophage viability with bergenin aloneMTT No reported viability reduction at 1, 3, 10, 30 μM[1]
PPRE-driven luciferase activity in RAW264.7 cellsRelative reporter activity Increased at 10 and 30 μM; p < 0.01 versus LPS group[1]

Literature-Reported Treatment Conditions

Treatment concentration
3, 10, 30 μM for cytokines/reporter; 1, 3, 10, 30 μM for viability
Exposure duration
24 h
Method
Cell treatment; cytokine and reporter arms included LPS stimulation.
Vehicle
Not specified for bergenin treatment.
Co-treatment
LPS 1 μg/mL in cytokine and reporter experiments; rosiglitazone 30 μM was a separate reporter comparator.
Reported limits
No cytokine IC50 or numerical reporter EC50 was reported in these locations; plotted magnitudes were not digitized.
Methods and source locations

Compound reported in the paper: Bergenin

Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.

Chemicals and Reagents; Cell Culture and Viability Assay; Luciferase Assay; Figure 3A–C and Figure 7D

IL-6 and TNF-α mRNA and secreted protein: Q-PCR and ELISA; mean ± SEM, three independent experiments — Figure 3B–C and corresponding cytokine Results

Macrophage viability with bergenin alone: MTT; 20 h exposure followed by 4 h with MTT (24 h total in Figure 3 caption) — Cell Culture and Viability Assay; Figure 3A

PPRE-driven luciferase activity in RAW264.7 cells: Luciferase reporter assay; mean ± SEM, three independent experiments — Luciferase Assay; Figure 7D

Urate-transporter expression in human HK-2 cells

Cell-based study · Human renal proximal tubular epithelial HK-2 cells exposed to soluble uric acid [2]

Bergenin at 50 and 100 μM countered uric-acid-associated ABCG2 downregulation and SLC2A9 upregulation. At 50 μM, the ABCG2 response was lost after PPARγ knockdown or antagonism; PPARγ knockdown did not alter the SLC2A9 response. These are expression and signaling measurements, not a direct transport-inhibition assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ABCG2 and SLC2A9 expressionDirection ABCG2 increased and SLC2A9 decreased relative to uric-acid-treated cells at 50 and 100 μM[2]
PPARγ dependence of ABCG2 responsePerturbation response PPARγ silencing or GW9662 prevented the bergenin-associated ABCG2 increase[2]
HK-2 viabilityCCK-8 No reported viability effect at 10–100 μM over 12 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
30, 50, 100 μM in transporter experiments; 50 μM in PPARγ perturbation arms
Exposure duration
2 h pretreatment followed by 10 h with uric acid; viability assessed after 12 h
Method
HK-2 cell treatment.
Vehicle
Bergenin-specific vehicle not identified; methods state inhibitors were dissolved in DMSO or water.
Co-treatment
Uric acid 8 mg/dL; PPARγ-siRNA or scrambled-siRNA arms; separate GW9662 10 μM and rosiglitazone 30 μM comparisons.
Reported limits
No direct urate-flux measurement in the adopted HK-2 experiment. Figure 5 caption provides the 2 h + 10 h timing; generic methods refer to 12 h exposure. The exact vehicle fraction is unavailable.
Methods and source locations

Compound reported in the paper: Bergenin

Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.

Reagents and Antibodies; Cell Culture; CCK-8; Figure 5A–G and associated HK-2 Results

ABCG2 and SLC2A9 expression: RT-qPCR and western blot; mean ± SEM, n = 3 — Results: Bergenin in vitro Treatment Regulates ... HK-2; Figure 5B–C

PPARγ dependence of ABCG2 response: PPARγ siRNA versus scrambled siRNA; western blot/RT-qPCR; GW9662 comparison — Results: Bergenin Promotes ABCG2 Expression by Activating PPARγ in HK-2 Cells; Figure 5E–G

HK-2 viability: CCK-8 assay — Figure 5A and caption

In Vivo Studies

In male C57BL/6 mice with established diabetic neuropathy, bergenin at 25 mg/kg intraperitoneally twice daily for 14 days reduced mechanical allodynia. Predose improvement was significant on days 8–14, but hyperglycemia persisted. These findings describe a preclinical behavioral response without demonstrating glucose normalization or human efficacy. [3]

Repeated-dose response in diabetic neuropathy

Animal study · Male C57BL/6 mice (25–30 g) with established streptozotocin-induced painful diabetic neuropathy [3]

Repeated intraperitoneal bergenin treatment reduced mechanical allodynia, with predose improvement appearing during days 8–14. Blood glucose remained elevated after the treatment course; the behavioral effect did not establish correction of diabetes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical nociceptive thresholdVon Frey 50% response threshold (g) Post-dose improvement; significant predose benefit on days 8–14 (p < 0.05 versus diabetic vehicle)[3]
Glycemia after repeated treatmentChange relative to baseline (%) Hyperglycemia persisted after 14 days of treatment[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Twice daily (every 12 h)
Treatment course
14 days
Vehicle
2% dimethyl sulfoxide in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bergenin 25 mg/kgDiabetic vehicle group and non-diabetic control; gabapentin 40 mg/kg orally twice daily was a separate active comparator.Mechanical allodynia decreased after dosing; predose benefit became significant on days 8–14. Hyperglycemia persisted after treatment.[3]
Bergenin 25 mg/kg
Model: Male C57BL/6 mice with established streptozotocin-induced painful diabetic neuropathy, beginning treatment in week 5.
Reported limits: Exposure concentrations and pharmacokinetic measurements were not provided for this regimen.
Methods and source locations

Compound reported in the paper: Bergenin

Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.

Sections 4.1–4.2, 4.4–4.5, 4.11; sections 2.2–2.3; Figures 1, 3–4

Mechanical nociceptive threshold: Von Frey up-and-down method; assessed immediately before and 1 h after the first daily dose; mean ± SD, n = 6 — Section 2.2; Figure 3; sections 4.4–4.5

Glycemia after repeated treatment: Blood glucose assessment at baseline, pretreatment day 1 and day 15; mean ± SD, n = 6 — Section 2.3; Figure 4 and caption

Bergenin 25 mg/kg · Sections 2.2–2.3; Figures 3–4 and captions; section 4.4

Specifications

Manufacturer Adooq Bioscience
CAS Number 477-90-7
Formula C14H16O9
Molecular Weight 328.3
Synonyms Cuscutin
SMILES
COC1=C(C=C2C(=C1O)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC2=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 63 mg/mL (191.91 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang K, Li YF, Lv Q, et al. Bergenin, Acting as an Agonist of PPARγ, Ameliorates Experimental Colitis in Mice through Improving Expression of SIRT1, and Therefore Inhibiting NF-κB-Mediated Macrophage Activation Frontiers in pharmacology (2018). PMID: 29375382 DOI: 10.3389/fphar.2017.00981 Source material
  2. [2] Chen M, Ye C, Zhu J, et al. Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia Frontiers in cell and developmental biology (2020). PMID: 32850823 DOI: 10.3389/fcell.2020.00703 Source material
  3. [3] Villarreal CF, Santos DS, Lauria PSS, et al. Bergenin Reduces Experimental Painful Diabetic Neuropathy by Restoring Redox and Immune Homeostasis in the Nervous System International journal of molecular sciences (2020). PMID: 32659952 DOI: 10.3390/ijms21144850 Source material

Publications

1 publication citing this product

  1. Barai P, .et al. , Behav Brain Res, 2019, Jan 1;356:18-40 PMID: 30118774

Added to your cart

View Cart Checkout
Loading...